SCHEMBL298399

SCHEMBL298399

O=C(c1cccc(NS(=O)(=O)c2cccc(OC(F)(F)F)c2)c1)c1c[nH]c2ncc(Cl)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 5/20 0.45
CYP3A4 P08684 1/20 0.44
KIT P10721 2/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
CYP2C9 P11712 3/20 0.43
CYP2C19 P33261 1/20 0.42
CCR9 P51686 1/20 0.42
BTK Q06187 1/20 0.42
SLC40A1 Q9NP59 1/20 0.41
BMPR1B O00238 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL298889 0.92 CCR9 (0.50) BRAFCYP3A4KITCYP2C9CYP2C19
SCHEMBL298324 0.89 CYP3A4 (0.47) BRAFCYP3A4KITHDAC3HDAC4
SCHEMBL297843 0.87 GAA (0.48) BRAFCYP3A4KITCYP2C9CYP2C19
SCHEMBL3710534 0.87 CYP3A4 (0.57) BRAFCYP3A4KITCYP2C9CYP2C19
SCHEMBL3709466 0.87 PGR (0.50) BRAFCYP3A4KITCYP2C9CYP2C19
SCHEMBL298707 0.84 CCR9 (0.46) BRAFCYP3A4KITCYP2C9CYP2C19
SCHEMBL298085 0.84 CYP19A1 (0.49) BRAFCYP3A4KITHDAC3HDAC4
SCHEMBL298196 0.84 PAK1 (0.44) CYP3A4KITHDAC3HDAC4HDAC1
SCHEMBL298104 0.83 CYP2C9 (0.53) BRAFCYP3A4KITCYP2C9CYP2C19
SCHEMBL297350 0.83 CYP3A4 (0.51) BRAFCYP3A4KITCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 EP disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF BRAF 1/4885CYP3A4 3611/4885KIT 1330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.